Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Historical / Mature / Divested Brands [legacy by Year
Historical / Mature / Divested Brands [legacy disclosures] — Vyndaqel/Hospital/Upjohn history ($M) ($M)
Pfizer Historical / Mature / Divested Brands [legacy: $10,233M in FY2019, down 18.0% from a year earlier. No newer figure appears in the documents we track.
Where the FY2019 figure comes from
Source: Form 10-K (filed 2020-02-27) ↗
Parent series shows historical Upjohn segment revenue prior to the November 2020 Viatris spin-off; child rows preserve brand histories.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Historical / Mature / Divested Brands [legacy disclosures] — Vyndaqel/Hospital/Upjohn history ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2019 | Dec 31, 2019 | 10,233 | -18.0% | Form 10-K (filed 2020-02-27) ↗ |
| FY2018 | Dec 31, 2018 | 12,484 | -7.2% | Form 10-K (filed 2020-02-27) ↗ |
| FY2017 | Dec 31, 2017 | 13,447 | – | Form 10-K (filed 2020-02-27) ↗ |
Breakdown
What makes up historical / Mature / Divested Brands [legacy
- BeneFIX (coagulation factor IX) [legacy through FY24] — Worldwide revenues ($M)381 · FY2024
- Premarin Family (conjugated estrogens) [legacy through FY24] — Worldwide revenues ($M)380 · FY2024
- Oxbryta (voxelotor — voluntarily withdrawn Sept 2024) [legacy through FY24] ($M)201 · FY2024
- Aromasin (exemestane) [legacy through FY25] ($M)450 · FY2025
- All Other Hospital [legacy through FY25] ($M)4,030 · FY2025
- Medrol (methylprednisolone) [legacy through FY23] — Worldwide revenues ($M)61 · FY2023
- Retacrit (epoetin alfa biosimilar) [legacy through FY23] — Worldwide revenues ($M)80 · FY2023
- Ruxience (rituximab biosimilar) [legacy through FY23] — Worldwide revenues ($M)26 · FY2023
- Zirabev (bevacizumab biosimilar) [legacy through FY23] — Worldwide revenues ($M)75 · FY2023
- Trazimera (trastuzumab biosimilar) [legacy through FY23] — Worldwide revenues ($M)33 · FY2023
- Sutent (sunitinib) [legacy through FY23] ($M)180 · FY2023
- Xalkori (crizotinib) [legacy through FY23] ($M)374 · FY2023
- Besponsa (inotuzumab ozogamicin) [legacy through FY23] ($M)236 · FY2023
- Bavencio alliance revenue [legacy through FY23] ($M)190 · FY2023
- Chantix / Champix (varenicline) [legacy through FY22] ($M)8 · FY2022
- Lyrica (pregabalin — Upjohn spin-off to Viatris Nov 2020) [legacy] ($M)3,321 · FY2019
- Lipitor (atorvastatin — Upjohn spin-off Nov 2020) [legacy] ($M)1,973 · FY2019
- Norvasc (amlodipine — Upjohn spin-off Nov 2020) [legacy] ($M)950 · FY2019
- Celebrex (celecoxib — Upjohn spin-off Nov 2020) [legacy] ($M)719 · FY2019
- Viagra (sildenafil — Upjohn spin-off Nov 2020) [legacy] ($M)497 · FY2019
Cite this data
StockData. (2026). Pfizer Historical / Mature / Divested Brands [legacy ($M), annual FY2017–FY2019 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/legacy-loe-brands
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.